Behaviors and Mental Disorders

All Conditions

Quality of Life

All Drugs and Chemicals

Herbal and Botanical

Butyric Acid

Histamine Antagonists

Histamine

Histamine phosphate

Neurotransmitter Agents

Cassava

4-6 grams of powder mixed with food and taken everyday starting 1 week prior-1 week post Radiation Therapy.

5 grams taken everyday starting 1 week prior-1 week post Radiation Therapy.

Participants will take the supplement as prescribed to determine if it can help with GI toxicity

Short Chain Fatty Acid

Participants taking this will be used as a control group compared to those receiving the SCFA supplement

Tapioca Flour

Flora Danquah

Shivani Sud, MD

The purpose of this study is to assess and compare GI toxicity from RT between subjects who receive therapeutic SCFA and those who receive placebo, in hopes of identifying a safe, low-cost therapeutic to reduce GI toxicity from therapeutic or environmental radiation.

Radiation therapy is a critical modality for treatment of urologic, gynecologic and gastrointestinal malignancies among others. Though advances in treatment techniques have reduced treatment-associated morbidity and mortality, normal tissue toxicity still limits dose escalation and treatment tolerance. Over 50% of patients receiving abdominal or pelvic radiation therapy (RT) develop clinically meaningful toxicity. Pharmacologic strategies to reduce normal tissue damage represent a tremendous unmet need in RT. Investigators propose a novel application of short chain fatty acids (SCFA) as a therapeutic to reduce incidence and severity of gastrointestinal (GI) toxicity from RT. Short chain fatty acids (SCFA) are fatty acids with fewer than six carbon atoms ingested or formed during bacterial fermentation of partially- and non-digestible polysaccharides carbohydrates. Patients who are enrolled will be randomized to receive SCFA supplements or a placebo, and will start taking it everyday one week prior to starting RT through 1 week after completing RT. Patients will keep a log of daily administration during the entire time while taking the study drug, and will complete patient reported outcomes (PROs) involving toxicities starting at baseline through 3 months post RT. The patient's treating physician will also complete an assessment of the patients toxicities starting at the baseline through follow up visits up to 5 years post RT, which will be used to compare to the PROs.

The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study

LCCC2032: The Effects of Short Chain Fatty Acid Supplementation on the Quality of Life and Treatment-related Toxicities in Subjects Receiving Abdominopelvic Radiotherapy: A Randomized Controlled Study

GI toxicities (PRO-CTCAE v5 for patients and CTCAE v5 for physicians) will be recorded and compared between the 2 groups to identify any differences.

Physicians will complete toxicity assessments using the CTCAE v5 at each visit with the patient up until 5 years post RT

Patients will complete PRO-CTCAE at each visit starting at baseline through 3 months after completing the study drug.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study	NCT04700527	Toxicity Radiation Toxic...	Short Chain Fat... Tapioca Flour	18 Years -	UNC Lineberger Comprehensive Cancer Center
The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study	NCT04700527	Toxicity Radiation Toxic...	Short Chain Fat... Tapioca Flour	18 Years -	UNC Lineberger Comprehensive Cancer Center

Spots Global Cancer Trial Database for short chain fatty acid